ImageneBio Q3 Loss Widens to $15.6M; Material Weakness Still Unremediated
IMA is trading near its 52-week low of $3.88 (2.3% above the low).
Summary
ImageneBio posted a $15.6M Q3 net loss and ended September with $126.6M in cash and securities, enough for at least 12 months of operations. The previously disclosed material weakness in internal controls remains unremediated, and $17.0M is still available under its Jefferies ATM.
Key Events · Earnings and Guidance · IMA
-
Q3 Net Loss of $15.6M
The three-month net loss was $15.6M versus $24.8M a year earlier, when merger-related stock compensation inflated the prior period; nine-month net loss was $36.4M.
-
Cash Down to $126.6M
Cash, cash equivalents and marketable securities fell to $126.6M at September 30, 2026 from $136.2M at June 30, 2026; management says this funds operations for at least the next 12 months.
-
Material Weakness Unremediated
Management concluded disclosure controls were not effective as of September 30, 2026 because of a material weakness in segregation of duties over journal entries and account reconciliations, which had not been remediated.
-
$17.0M ATM Still Available
The August 2026 at-the-market facility with Jefferies has $17.0M of common stock remaining available for sale as of September 30, 2026.
Analysis · IMA · Life Sciences
Cash and investments fell by roughly $9.6M in Q3, leaving ImageneBio with $126.6M at September — enough to fund operations for at least the next 12 months, though the company still expects to need substantial additional capital for its sole clinical asset, olevaprubart. The bigger governance issue: the material weakness in internal controls (incompatible duties over journal entries and account reconciliations) remains unremediated as of September 30, 2026, and management concluded disclosure controls were not effective. With the stock near its 52-week low, the $17.0M at-the-market facility with Jefferies is the near-term dilution lever if the equity market stays closed. Phase 2b atopic dermatitis topline is guided to Q4 2027, and the alopecia areata Phase 2 is expected to start by end-2026.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMA was trading at $3.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.1M. The 52-week trading range was $3.88 to $8.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.